Tricida (TCDA) Set to Announce Earnings on Monday

Tricida (NASDAQ:TCDAGet Rating) will be releasing its earnings data after the market closes on Monday, August 8th. Analysts expect Tricida to post earnings of ($0.52) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Tricida (NASDAQ:TCDAGet Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.13. On average, analysts expect Tricida to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tricida Trading Up 0.4 %

Shares of NASDAQ:TCDA opened at $10.86 on Friday. The business’s 50-day moving average is $9.74 and its 200 day moving average is $9.41. Tricida has a 1 year low of $3.80 and a 1 year high of $12.45. The firm has a market capitalization of $601.92 million, a P/E ratio of -3.76 and a beta of 0.68. The company has a debt-to-equity ratio of 584.92, a current ratio of 5.12 and a quick ratio of 5.12.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group cut their price objective on Tricida from $22.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, May 24th.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par acquired 91,506 shares of the business’s stock in a transaction dated Monday, June 6th. The shares were acquired at an average cost of $9.35 per share, with a total value of $855,581.10. Following the completion of the acquisition, the insider now owns 5,865,160 shares of the company’s stock, valued at $54,839,246. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders have bought 999,004 shares of company stock valued at $9,517,079. Company insiders own 70.40% of the company’s stock.

Institutional Trading of Tricida

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in Tricida during the first quarter worth about $45,000. Royal Bank of Canada acquired a new stake in Tricida during the first quarter worth about $55,000. Bank of America Corp DE grew its holdings in Tricida by 290.5% during the first quarter. Bank of America Corp DE now owns 7,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,505 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Tricida during the first quarter worth about $87,000. Finally, Ergoteles LLC acquired a new stake in Tricida during the first quarter worth about $97,000. 79.28% of the stock is owned by institutional investors and hedge funds.

About Tricida

(Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Further Reading

Earnings History for Tricida (NASDAQ:TCDA)

Want More Great Investing Ideas?

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with's FREE daily email newsletter.